Clinical trial
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in…
NCT00229658 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00229658 |
|---|---|
| Title | An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes |
| Official title | A Prospective, Open-Label, Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes Following SYMLIN Introduction Into the Marketplace |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | pramlintide acetate |
| Enrollment | 1,297 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Sep 30, 2005 |
| Last update posted | Mar 25, 2015 |
| Countries | United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: